GSK (GSK) said Monday that it is partnering with the University of Oxford to investigate cancer prevention through vaccination, with GSK committing up to 50 million British pounds ($62.6 million) in funding over a minimum of three years.
The GSK-Oxford Cancer Immuno-Prevention program will focus on understanding precancer biology to uncover how cancer forms and identify potential vaccine strategies, the organizations said.
GSK's shares were up over 1% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.